About EdisonTech Medical
"The real measure of success is the number of experiments that can be crowded into twenty-four hours."
- Thomas Edison
EdisonTech Medical Vision
Illuminating rare lives with innovative science.
"As a rare disease R&D team, we know patients may be few, but to their families, a cure is 100% of their world."
Marco，Head of Project
HLZ Leadership
.png)
Target Market of EdisonTech Medical
HIV:
We focus on the development of breakthrough biotechnology, utilizing precision gene editing to block viral replication and applying immunotherapy to eradicate latent viral reservoirs. Our goal is to break the constraint of lifelong medication, bringing the dawn of a 'Functional Cure' to HIV patients worldwide.
Down Syndrome:
We focus on gene regulation research for Trisomy 21. Through cutting-edge chromosome silencing technology and prenatal neuroprotective targeted therapies, we are dedicated to blocking gene overexpression during early embryonic development. By breaking the limitations of traditional medicine, we aim to achieve the foundational prevention of and intervention for Down syndrome.
EdisonTech Medical Research Directions
Juvenile Amyotrophic Lateral Sclerosis (Juvenile ALS) / Progressive Bulbar Palsy:
Disease Mechanism: This is an extremely rare subtype of ALS (Lou Gehrig's disease) that typically manifests during childhood or adolescence. It involves the unexplained and rapid degeneration of motor neurons, leading to a swift loss of the patient’s ability to walk, swallow, and breathe.
Current Therapeutic Landscape: While a few disease-modifying drugs exist for adult-onset ALS (such as Riluzole and Relyvrio) to slow disease progression, there are virtually no effective, targeted therapies available for the rapidly progressing juvenile or hereditary forms of ALS, resulting in an exceptionally high mortality rate.
Neurofibromatosis Type 2 (NF2):
Disease Mechanism: Driven by mutations in the NF2 gene, this condition causes the continuous growth of multiple benign tumors throughout the body, particularly affecting bilateral acoustic nerves, meninges, and the spinal cord. This leads to symptoms such as hearing loss, balance disorders, paralysis, and can even be life-threatening.
Current Therapeutic Landscape: While targeted therapies (such as Selumetinib) are available for NF1, there are currently no approved targeted therapies for NF2. Patients are left with no choice but to undergo repeated, high-risk surgical resections or radiation therapies.
EdisonTech Medical Future
.png)
https://www.hlz-group.com/edisontech-medical
HLZ GROUP, 100 Gansevoort Street, New York, NY 10014
This website is governed by and subject to the laws of the United States and the Hong Kong SAR.
.
By using this website, you agree that your data, contributions, and user-generated content may be utilized to train, improve, and develop our artificial intelligence and machine learning models.
© 2026 EdisonTech Medical All Rights Reserved